JP2020503359A5 - - Google Patents

Info

Publication number
JP2020503359A5
JP2020503359A5 JP2019536507A JP2019536507A JP2020503359A5 JP 2020503359 A5 JP2020503359 A5 JP 2020503359A5 JP 2019536507 A JP2019536507 A JP 2019536507A JP 2019536507 A JP2019536507 A JP 2019536507A JP 2020503359 A5 JP2020503359 A5 JP 2020503359A5
Authority
JP
Japan
Prior art keywords
seq
sequence
nos
netrin
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019536507A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503359A (ja
JP7211952B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/050289 external-priority patent/WO2018127570A1/en
Publication of JP2020503359A publication Critical patent/JP2020503359A/ja
Publication of JP2020503359A5 publication Critical patent/JP2020503359A5/ja
Priority to JP2022151769A priority Critical patent/JP2022176250A/ja
Application granted granted Critical
Publication of JP7211952B2 publication Critical patent/JP7211952B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019536507A 2017-01-05 2018-01-05 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療 Active JP7211952B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022151769A JP2022176250A (ja) 2017-01-05 2022-09-22 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305014 2017-01-05
EP17305014.7 2017-01-05
PCT/EP2018/050289 WO2018127570A1 (en) 2017-01-05 2018-01-05 Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022151769A Division JP2022176250A (ja) 2017-01-05 2022-09-22 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療

Publications (3)

Publication Number Publication Date
JP2020503359A JP2020503359A (ja) 2020-01-30
JP2020503359A5 true JP2020503359A5 (cg-RX-API-DMAC7.html) 2022-05-20
JP7211952B2 JP7211952B2 (ja) 2023-01-24

Family

ID=57838304

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019536507A Active JP7211952B2 (ja) 2017-01-05 2018-01-05 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療
JP2022151769A Pending JP2022176250A (ja) 2017-01-05 2022-09-22 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022151769A Pending JP2022176250A (ja) 2017-01-05 2022-09-22 ネトリン-1干渉薬及び免疫チェックポイント阻害薬による併用治療

Country Status (10)

Country Link
US (2) US12162932B2 (cg-RX-API-DMAC7.html)
EP (1) EP3565837B1 (cg-RX-API-DMAC7.html)
JP (2) JP7211952B2 (cg-RX-API-DMAC7.html)
KR (1) KR102679324B1 (cg-RX-API-DMAC7.html)
CN (1) CN110291105B (cg-RX-API-DMAC7.html)
AU (1) AU2018205730B2 (cg-RX-API-DMAC7.html)
CA (1) CA3048347A1 (cg-RX-API-DMAC7.html)
EA (1) EA039433B1 (cg-RX-API-DMAC7.html)
IL (1) IL267775B1 (cg-RX-API-DMAC7.html)
WO (1) WO2018127570A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3565837B1 (en) 2017-01-05 2024-04-10 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
MX2024001308A (es) * 2021-07-27 2024-05-23 Netris Pharma Deteccion de netrina-1, prueba complementaria y terapia basada en radiaciones.
CA3246346A1 (en) * 2022-03-29 2023-10-05 Netris Pharma NEW MCL-1 INHIBITOR AND COMBINATION OF MCL-1 AND A BH3 MIMETIC, SUCH AS A BCL-2 INHIBITOR
WO2024095723A1 (ja) 2022-11-02 2024-05-10 シチズン・システムズ株式会社 プリンタ

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
ES2601352T3 (es) 2006-02-28 2017-02-14 Centre National De La Recherche Scientifique (Cnrs) Cribado para compuestos anti-cáncer usando actividad de netrina-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2609430A1 (en) 2010-08-26 2013-07-03 F.Hoffmann-La Roche Ag Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
EP2708231A1 (en) 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
EP2893939A1 (en) * 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
UA122479C2 (uk) * 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
CN104083762A (zh) * 2014-06-27 2014-10-08 中国科学院生物物理研究所 用于阻断Netrin-1与CD146之间的相互作用的试剂及其肿瘤治疗用途
NZ738406A (en) 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
EP3565837B1 (en) 2017-01-05 2024-04-10 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs

Similar Documents

Publication Publication Date Title
Jeong et al. Novel anti-4-1BB× PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
JP7284557B2 (ja) 医薬組成物
HRP20220629T1 (hr) Anti-cd73 antitijela i njihove upotrebe
JP2018501197A5 (cg-RX-API-DMAC7.html)
JP2018508483A5 (cg-RX-API-DMAC7.html)
JP2022505679A5 (cg-RX-API-DMAC7.html)
HRP20210876T1 (hr) Anti-tmprss2 antitijela i fragmenti koji vezuju antigen
JP2019524693A5 (cg-RX-API-DMAC7.html)
JP2017535257A5 (cg-RX-API-DMAC7.html)
EA202092460A1 (ru) Антитела к ox40 и способы применения
IL253462B (en) Cancer treatment with monoclonal antibodies against latency-associated peptide
RU2016114504A (ru) Би- или полиспецифические полипептиды, связывающие поверхностные антигены иммунных эффекторных клеток и антигены hbv для лечения инфекций bv и ассоциированных с ними состояний
JP2016536322A5 (cg-RX-API-DMAC7.html)
JP2018523493A5 (cg-RX-API-DMAC7.html)
JP2016539096A5 (cg-RX-API-DMAC7.html)
JP2016527286A5 (cg-RX-API-DMAC7.html)
RU2017105118A (ru) Нейтрализация ингибирующих путей в лимфоцитах
JP2019511212A5 (cg-RX-API-DMAC7.html)
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP2018532383A5 (cg-RX-API-DMAC7.html)
HRP20201528T1 (hr) Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama
MY188237A (en) Anti-pd-l1 antibodies and uses thereof
HRP20201785T1 (hr) Multivalentni i multispecifični fuzijski proteini koji vežu dr5
RU2018125490A (ru) Нейтрализация ингибиторных путей в лимфоцитах
Häsler et al. VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry